Tudor Investment Corp
CLYM

Tudor Investment Corp’s Climb Bio CLYM Stock Holding History

Tudor Investment Corp’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29,466
Closed -$80.7K – 2885
2024
Q1 		$80.7K Sell
29,466
-24
-0.1% -$66 ﹤0.01% 2104
2023
Q4 		$79.6K Sell
29,490
-214
-0.7% -$557 ﹤0.01% 2255
2023
Q3 		$78.1K Sell
29,704
-2
-0% -$5 ﹤0.01% 2164
2023
Q2 		$83.2K Hold
29,706
– – ﹤0.01% 2305
2023
Q1 		$86K Sell
29,706
-901
-3% -$3.1K ﹤0.01% 2269
2022
Q4 		$112K Sell
30,607
-12
-0% -$36 ﹤0.01% 2213
2022
Q3 		$99K Hold
30,619
– – ﹤0.01% 2154
2022
Q2 		$92K Sell
30,619
-15,473
-34% -$73.2K ﹤0.01% 1929
2022
Q1 		$387K Sell
46,092
-149,366
-76% -$1.39M 0.01% 1415
2021
Q4 		$2.04M Sell
195,458
-91,836
-32% -$1.37M 0.03% 613
2021
Q3 		$5.17M Buy
+287,294
New +$5.94M 0.08% 258

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp's CLYM Position: Q2 2024 in Review

Tudor Investment Corp sold out of Climb Bio (CLYM) in Q2 2024, closing a stake of 29,466 shares — an estimated $80.7K sold.

Tudor Investment Corp first reported a position in CLYM in Q3 2021 and held it in 11 quarters. The position peaked at $5.17M in Q3 2021. 47 funds tracked by Wall St. Rank hold CLYM as of Q2 2024.

  • Tudor Investment Corp reported no remaining Climb Bio position as of Q2 2024 after selling out during the quarter.
  • Tudor Investment Corp sold 29,466 Climb Bio shares in Q2 2024, an estimated $80.7K.
  • Tudor Investment Corp first reported a position in Climb Bio in Q3 2021 and held it in 11 quarters.
  • Tudor Investment Corp's Climb Bio position peaked at $5.17M in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Climb Bio as of Q2 2024.

Based on Tudor Investment Corp's 13F filing for Q2 2024, filed 14 Aug 2024.